


# Realizing the Objectives of the ICMRA Postapproval Change Collaborative Assessment Pilot

Sau (Larry) Lee, Ph.D.  
Deputy Director of Science  
Office of Pharmaceutical Quality  
Center for Drug Evaluation and Research

The 12th Asia Partnership Conference of Pharmaceutical Associations  
April 18, 2023

# PAC Sub-Working Group

## Collaborative Pilots: CMC-Related PACs and Hybrid Inspections



Scan the 2D barcode using your phone for further information



The screenshot shows the ICMRA website header with the logo and a navigation menu including COVID-19, About Us, Meetings, Strategic Initiatives, Relationships, News, Links, and Contact Us. Below the header is a breadcrumb trail: Home > Pharmaceutical Quality Knowledge Management System (PQKMS). The main content area features the title "PQQMS Collaborative Pilot Information and Application Forms" and a paragraph explaining the pilot programs. A list of links is provided, grouped by a red bracket on the right side of the page.

ICMRA provides a global architecture to support enhanced communication, information sharing, crisis response and address regulatory science issues.

COVID-19 About Us Meetings Strategic Initiatives Relationships News Links Contact Us

Home > Pharmaceutical Quality Knowledge Management System (PQKMS)

### PQQMS Collaborative Pilot Information and Application Forms

Following the July 2021 ICMRA-Industry virtual workshop on enabling manufacturing capacity in the COVID-19 pandemic, ICMRA is commencing two pilot programs focusing on i) collaborative assessment with initial focus on chemistry, manufacturing, and control (CMC) post-approval changes and ii) collaborative hybrid inspections. The overall aim of these pilots is to improve manufacturing capacity for production of critical medicines and facilitate collaborative assessments and inspections by multiple regulatory authorities (see links for further information).

- [Call for Applications to PQ Pilots](#)
- [Application Form for Collaborative Assessment](#)
- [Application Form for Collaborative Hybrid Inspection](#)
- [Overview of Collaborative Assessment](#)
- [Overall Plan for Collaborative Assessment](#)
- [Overview of Hybrid Inspection](#)
- [Overall Plan for Hybrid Inspection](#)

See links for all information needed concerning the collaborative pilots

2

# Main Workshop Goals

held on 07-08 July 2021

- Opportunity for an **exchange of views between regulators and the pharmaceutical industry** on the regulatory flexibilities introduced to enhance the manufacturing capacity of COVID-19 products
- **Identification of key enablers and bottlenecks** limiting the use of regulatory flexibilities, in addition to the most effective mechanisms that enabled increased manufacturing capacity
- Workshop will serve as a **catalyst...leading to greater convergence and further efficiencies** in global chemistry, manufacturing, and control (CMC) assessment and inspection activities

ICMRA-Industry Virtual Workshop Report  
on Enabling Manufacturing Capacity in  
the COVID-19 Pandemic




# Vision:

- **Advance international regulatory effort through strategic partnership** among regulatory agencies and industry to facilitate faster access and continuous supply of high-quality medicines to patients across regions considering that the development, manufacture, and supply of medicines is global
- The ICMRA workshop highlighted the need for more **convergence on CMC aspects between regions** to allow faster supply of critical medicines to patients and the need to overcome logistic challenges related to quality assessment and inspection.

# Key Objectives of Pilots

- **Develop and share an initial framework** for collaborative assessment, which provides a platform for multiple regulatory authorities to participate in a collaborative assessment of post-approval CMC changes and participation of hybrid inspections
- Identify **misalignments, differences**, and potential areas for **alignment or harmonization** across regions
- Providing industry with **experience submitting the same CMC information** for the same product and manufacturing facilities to multiple regulators
- Identifying types of products where **“early wins”** are likely to be most achievable.
- **Increasing confidence** among both regulatory authorities and industry regarding the Pharmaceutical Quality Knowledge Management System (PQ KMS) capabilities that could be operationalized and how to approach regulatory collaboration to achieve the greatest success



# **ICMRA Pilot Program for Collaborative Assessment of CMC Post-approval Changes**

# Aim of the ICMRA Collaborative Assessment Pilot

- Develop a framework, which provides a platform for multiple regulatory agencies to participate in a collaborative assessment of post-approval CMC changes including post-approval change management protocols (PACMPs)
- The applicants' responses will be shared between the participating quality assessors, who will work towards a common approach to the application assessment and decision making.
- Deliver a single list of questions to the applicant wherever possible, however a stated goal of the pilot is to identify misalignments, differences, and potential areas for further convergence or harmonization across regions
- Develop best practices in the quality assessment of CMC post-approval changes and share learnings to build further collaborations in assessment

# Regulatory Submission Considerations for the Collaborative Assessment Pilot:

- The proposal should be based on a planned CMC post-approval change(s).
- Products that are distributed under an emergency use mechanism and not a marketing application should not be considered.
- The product(s) involved should be intended for the treatment of patients with COVID-19, breakthrough/PRIME products, or medically necessary.
- The changes should be intended to be submitted to multiple regions concurrently.
- The submission should ideally involve an area where there is an opportunity for regulatory convergence.
- A common dataset should be provided to all participating agencies.
- There should be no restrictions on sharing data among the regulatory agencies participating in the pilot.
- There should be agreement to publicly share some high-level data and results of the collaborative assessment.
- Industry representatives are willing to participate in a virtual discussion meeting to have open dialogues with regulators from multiple regions on technical and regulatory issues related to their applications.



# Early engagement with Industry



- Established a partnership between regulatory authorities and industry to accomplish our ambitious vision
- Raised awareness of the pilot scope and overall aim and clearly communicate what is feasible to achieve
- Shared first outline of the proposed pilot – Sept. 2021
- Invited input and suggestions from industry to improve and fine tune the details of the pilot, ensuring we learn from past experiences and other ongoing efforts – Feb. 2022
- Requested that industry give an early signal if they foresee any obstacles to the successfully running of the pilot which have not been considered by regulators – Feb. 2022
- Early flag for timely identification of candidate cases

# Realistic Expectations:

- Harmonisation and the desired convergence cannot be achieved only through the few pilot cases
- Whilst the aspiration is to achieve a single outcome in each case, unless there are different regional legal/ regulatory requirements, the focus will be to pave the path for the future, rather than solely the case outcomes
- Each region is still bound to its existing Regulatory / legal framework; any differences cannot be bridged through this pilot

# Progress of ICMRA Pilots

- Open call to Industry for both pilots since June 2022
- 7 proposals submitted for the collaborative assessment
  - ✓ Expect to accept three proposals
  - ✓ **Two proposals have been accepted**
- The pilots remain open - encourage new proposals



ICMRA provides a global architecture to support enhanced communication, information sharing, crisis response and address

COVID-19 About Us Meetings Strategic Initiatives Relationships News Links Contact Us

Home > News > International pilot programmes to streamline regulatory assessments and inspections – call for industry applications

## International pilot programmes to streamline regulatory assessments and inspections – call for industry applications


The International Coalition of Medicines Regulatory Authorities (ICMRA) is inviting industry sponsors to participate in pilot programmes focusing on i) collaborative assessments of chemistry, manufacturing and control (CMC) related post-approval changes and ii) hybrid inspections"[\[https://www.icmra.info/drupal/strategicinitiatives/pqkms\]](https://www.icmra.info/drupal/strategicinitiatives/pqkms).

The main objectives of the two pilots include:

- Development of an initial common framework for collaborative assessment and hybrid inspections;
- Identification of best practices and standards in the quality assessment of CMC-related post-approval changes and collaborative hybrid inspections to inform relevant quality assessments;
- Delivery of a single list of questions to the sponsor or manufacturer, wherever possible, and identification of any misalignments, differences, and potential areas for alignment or harmonization across participating regulators' regions;
- Sharing of the sponsors' or manufacturer's responses with the participating quality assessors/inspectors who will work towards a common approach to assessment and decision making;
- Identification of the conditions (products/ cases) on which cross-regional collaboration efforts in the collaborative assessment and hybrid inspection pilots should focus and the development of recommendations for a future cross-regional pathway(s) to be pursued by ICMRA.

# Progress of ICMRA Pilots

- 1<sup>st</sup> accepted collaborative assessment proposal
  - PACMP for addition of new DP manufacturing and testing sites for a biological molecule
  - Up to 6 participating regulatory authorities
  - Regulatory submission expected in April 2023
- 2<sup>nd</sup> accepted collaborative assessment
  - PACMP for DS/DP/QC site transfer for a biological molecule
  - 2 participating regulatory authorities initially
  - Regulatory submission received in January 2023
  - 1st set of common information requests sent in March 2023



The screenshot shows the ICMRA website header with the logo and a navigation menu. The main content area features a news article with the following text:

ICMRA provides a global architecture to support enhanced communication, information sharing, crisis response and address

COVID-19 About Us Meetings Strategic Initiatives Relationships News Links Contact Us

Home > News > International pilot programmes to streamline regulatory assessments and inspections – call for industry applications

### International pilot programmes to streamline regulatory assessments and inspections – call for industry applications


The International Coalition of Medicines Regulatory Authorities (ICMRA) is inviting industry sponsors to participate in pilot programmes focusing on i) collaborative assessments of chemistry, manufacturing and control (CMC) related post-approval changes and ii) hybrid inspections"[\[https://www.icmra.info/drupal/strategicinitiatives/pqkms\]](https://www.icmra.info/drupal/strategicinitiatives/pqkms).

The main objectives of the two pilots include:

- Development of an initial common framework for collaborative assessment and hybrid inspections;
- Identification of best practices and standards in the quality assessment of CMC-related post-approval changes and collaborative hybrid inspections to inform relevant quality assessments;
- Delivery of a single list of questions to the sponsor or manufacturer, wherever possible, and identification of any misalignments, differences, and potential areas for alignment or harmonization across participating regulators' regions;
- Sharing of the sponsors' or manufacturer's responses with the participating quality assessors/inspectors who will work towards a common approach to assessment and decision making;
- Identification of the conditions (products/ cases) on which cross-regional collaboration efforts in the collaborative assessment and hybrid inspection pilots should focus and the development of recommendations for a future cross-regional pathway(s) to be pursued by ICMRA.

# Learnings of ICMRA Pilots

- Positive and productive collaboration
- A lot of effort taken to align regulatory processes and timelines for ICMRA collaborative assessment pilot among different regulatory authorities
  - Generally use the most aggressive timeline
- Lack of a common IT platform for information sharing and collaborative assessment
- Regional requirements
  - PACMP DS – 1 out of 16 comments/questions
  - PACMP DP – 1 out of 13 comments/questions



ICMRA provides a global architecture to support enhanced communication, information sharing, crisis response and address

COVID-19 About Us Meetings Strategic Initiatives Relationships News Links Contact Us

Home > News > International pilot programmes to streamline regulatory assessments and inspections – call for industry applications

## International pilot programmes to streamline regulatory assessments and inspections – call for industry applications

The International Coalition of Medicines Regulatory Authorities (ICMRA) is inviting industry sponsors to participate in pilot programmes focusing on i) collaborative assessments of chemistry, manufacturing and control (CMC) related post-approval changes and ii) hybrid inspections"[\[https://www.icmra.info/drupal/strategicinitiatives/pqkms\]](https://www.icmra.info/drupal/strategicinitiatives/pqkms).

The main objectives of the two pilots include:

- Development of an initial common framework for collaborative assessment and hybrid inspections;
- Identification of best practices and standards in the quality assessment of CMC-related post-approval changes and collaborative hybrid inspections to inform relevant quality assessments;
- Delivery of a single list of questions to the sponsor or manufacturer, wherever possible, and identification of any misalignments, differences, and potential areas for alignment or harmonization across participating regulators' regions;
- Sharing of the sponsors' or manufacturer's responses with the participating quality assessors/inspectors who will work towards a common approach to assessment and decision making;
- Identification of the conditions (products/ cases) on which cross-regional collaboration efforts in the collaborative assessment and hybrid inspection pilots should focus and the development of recommendations for a future cross-regional pathway(s) to be pursued by ICMRA.

# ICMRA PAC-Sub Working Group

- Sean Barry, HPRA
- Karl Cogan, HPRA
- Brendan Cuddy, EMA
- Evdokia Korakianiti, EMA
- Kotzagiorgis Evangelos, EMA
- Theresa Mullin, FDA
- Sau (Larry) Lee, FDA
- William Lewallen, FDA
- Susan Polifko, FDA
- Stelios Tsinontides, FDA
- Yasuda Naoyuki, MHLW
- Matsukura Yuuji, MHLW
- Yasuhiro Kishioga, PMDA
- Ueda Mami, PMDA
- Togashi Mika, PMDA
- Inuzuka Hiroto, PMDA



